Show simple item record

dc.contributor.authorRankgoane‑Pono, Goabaone
dc.contributor.authorTshikuka, Jose Gaby
dc.contributor.authorMagafu, Mgaywa Gilbert Mjungu Damas
dc.contributor.authorMasupe, Tiny
dc.contributor.authorMolefi, Mooketsi
dc.contributor.authorHamda, Shimeles Genna
dc.contributor.authorSetlhare, Vincent
dc.contributor.authorTapera, Roy
dc.contributor.authorMbongwe, Bontle
dc.date.accessioned2018-11-15T07:58:05Z
dc.date.available2018-11-15T07:58:05Z
dc.date.issued2018-02-01
dc.identifier.citationRankgoane‑Pono, G. et a.l (2018) Incidence of diabetes mellitus‑related comorbidities among patients attending two major HIV clinics in Botswana: a 12‑year retrospective cohort study. BMC Research Notes. Vol. 11, No. 90. pp. 1-5en_US
dc.identifier.issn1756-0500
dc.identifier.urihttp://hdl.handle.net/10311/1827
dc.description.abstractObjectives: Exposure to combination antiretroviral therapy (cART) is associated with the development of diabetes mellitus related comorbidities (DRCs). This study aims to: (i) estimate the incidence of DRCs among cART recipients, (ii) assess the time-to-event (development of DRC) and, (iii) compare survival function between recipients on first-line regimen and those on second-, third-line cART regimen. Results: The incidence of DRCs was 26.8/1000 person-years, with total time of exposure of 3316 person-years. The average time to event for all the three regimens was 11.72 ± 0.20 years. The first-line cART regimen had a shorter mean ± SE of 10.59 ± 0.26 years to the event compared to 12.69 ± 0.24 years for the second-, third-line cART regimen. Recipients on the first-line had a shorter survival than recipients on second-, third-line cART (Log-rank X2 = 8.98, p < 0.003). Data from this study showed that the risk of developing DRCs per year of exposure was significantly greater for patients on first-line compared to those who were on second-, third-line regimen; which, suggests that monitoring of cART long-term side effects and regular reviewing of cART regimens is important. Meticulous selection of drug combinations is a key to improving recipients’ survival.en_US
dc.language.isoenen_US
dc.publisherBioMed Central, www.biomedcentral.comen_US
dc.subjectIncidenceen_US
dc.subjectdiabetes-related comorbiditiesen_US
dc.subjectcombination antiretroviral therapyen_US
dc.subjectPLHIVen_US
dc.subjectBotswanaen_US
dc.titleIncidence of diabetes mellitus‑related comorbidities among patients attending two major HIV clinics in Botswana: a 12‑year retrospective cohort studyen_US
dc.typePublished Articleen_US
dc.linkhttps://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-018-3144-9en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record